Lung cancer remains a formidable health challenge, particularly when advanced to a stage where treatment becomes increasingly complex. In recent years, a ray of hope has emerged in the form of Lorbrena (Lorlatinib), a medication approved by the U.S. Food and Drug Administration (FDA) on 2nd November 2018.
Indication
Adults with metastatic NSCLC whose tumors have been found to express the ALK gene through an FDA-approved test are eligible to receive Lorbrena. Additionally, the FDA’s action turns the 2018 accelerated approval into a complete approval. The Real-Time Oncology Review (RTOR) pilot program of the FDA resulted in the approval of the application.
Statistical Significance
Clinical trials revealed impressive results, with the Objective Response Rate (ORR) reaching up to 48% and a median Progression-Free Survival (PFS) of around 12.5 months. These statistics underscore Lorbrena’s effectiveness in controlling the progression of advanced lung cancer.
Recent Advancements in Medicine
Lorbrena is a testament to the remarkable advancements in precision medicine. By specifically targeting and inhibiting ALK gene activity, Lorbrena enhances treatment efficacy and reduces side effects, improving patients’ quality of life during therapy. This precision approach reflects a growing trend in oncology toward personalized treatment based on genetic profiles.
Contraindications
Lorbrena is contraindicated for patients with a known hypersensitivity to Lorlatinib or its components. To prevent adverse events, healthcare professionals should assess patients for any history of severe hypersensitivity reactions. Patients are not advised to consume Lorbrena if they take certain other medicines called strong CYP3A inducers.
Dosage and Administration
The recommended dosage of Lorbrena is 100mg, taken orally once daily, with or without food. Dosage adjustments may be necessary to respond to adverse reactions or ensure adequate disease control. Healthcare providers should offer guidance regarding the correct administration of Lorbrena.
Drug Interaction
Patients taking potent CYP3A inducers should avoid Lorbrena. Concurrent use of strong CYP3A inhibitors and moderate CYP3A inducers should be avoided, and if necessary, monitor ALT, AST, and bilirubin levels.
Warnings and Precautions
Central Nervous System Effects: Lorbrena may cause cognitive effects, hallucination, or mood changes. Patients should be monitored for these symptoms, and the dose should be adjusted or treatment discontinued.
Hypercholesterolemia: Lorbrena may elevate cholesterol levels. Regular monitoring of lipid panels is recommended, and cholesterol-lowering agents may be required, like adjustment of medication to manage these elevated levels.
Pulmonary Effects: Patients should be closely monitored for new or worsening respiratory symptoms. Dosing adjustments or discontinuation of Lorbrena may be necessary. It is crucial to report any new or worsening symptoms related to lung issues, such as difficulty breathing, shortness of breath, cough, or fever, to your healthcare provider.
Heart Problems: Lorbrena may cause (slow heart rhythms). Your healthcare provider should perform electrocardiogram (ECG) tests to monitor your heart rhythm before and during treatment. If you experience dizziness, fainting, or irregular heartbeats, inform your healthcare provider immediately.
High Blood Pressure: Regular blood pressure monitoring is essential during Lorbrena treatment. Healthcare providers may need to initiate or modify blood pressure medications as needed.
High Blood Sugar: Lorbrena may elevate blood sugar levels. Regular blood tests are necessary to monitor your blood sugar levels before and during treatment.
Pancreatic Enzyme Elevation: Patients should be evaluated for signs and symptoms of pancreatic enzyme elevation. Dosing interruptions or adjustments may be required in response.
Conclusion
Lorlatinib Pfizer continues to advance precision medicine in lung cancer treatment. This medicine’s FDA approval marked a pivotal milestone in ALK-positive NSCLC treatment, offering hope with its precision and manageable side effects. Yet, adhering to its warnings and precautions is vital for safe use. Lorbrena exemplifies oncology’s remarkable progress in precision medicine, bringing fresh hope to advanced lung cancer patients. Lorbrena 100mg price in India depends on the product requirement. Request more details by contacting our Patient Support Team at (+91) 93157 05373 or help@sansfro.com.
Reference:
Recent posts
-
February 27, 2024Etoposide: Uses and Indications
-
February 26, 2024Palbociclib in Breast Cancer Treatment
-
February 26, 2024
Aprepitant in Cancer Treatment
